학술논문
Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
Document Type
Clinical report
Author
Source
Journal of Arrhythmia. August 2023, Vol. 39 Issue 4, p546, 10 p.
Subject
Language
English
ISSN
1880-4276
Abstract
INTRODUCTION Atrial fibrillation (AF) is the most common cardiac arrhythmia, with 1%–4% of the general population being affected.[sup.1–4] The prevalence of AF in South Korea has been increasing over the [...]
: Background: The real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population. Methods: One‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries. Results: Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age ( Conclusions: The outcomes in the Korean ETNA‐AF population are like those in the global ETNA‐AF population, with overall low event rates of stroke, major bleeding and all‐cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.
: Background: The real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population. Methods: One‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries. Results: Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age ( Conclusions: The outcomes in the Korean ETNA‐AF population are like those in the global ETNA‐AF population, with overall low event rates of stroke, major bleeding and all‐cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.